Comparison of nucleoside reverse transcriptase inhibitor use as part of first-line therapy in a serbian and a UK HIV clinic

HIV Clinical Trials

Volumn 10, Issue 5, 2009, Pages 306-313

  Dragovic, G J ^a   Smith, C J ^b   Jevtovic, D J ^a   Johnson, M A ^c   Ranin, J ^a   Salemovic, D ^a   Youle, M S ^c  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

High income country; Low middle income country; Mitochondrial toxicity; NRTIs usage

Indexed keywords

DIDANOSINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

ADULT; ARTICLE; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; HOSPITAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MITOCHONDRION; SERBIA; SOCIOECONOMICS; TREATMENT OUTCOME; UNITED KINGDOM;

ADULT; DIDANOSINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GREAT BRITAIN; HIV INFECTIONS; HOSPITALS; HUMANS; MALE; MITOCHONDRIA; REVERSE TRANSCRIPTASE INHIBITORS; SERBIA; SOCIOECONOMIC FACTORS; STAVUDINE; TREATMENT OUTCOME;

EID: 74149092542     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1005-306     Document Type: Article

References (34)

1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodefi ciency virus infection. N Engl J Med. 1998;338(13):853-860 (Pubitemid 28135961)
2. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362:22-29 (Pubitemid 36835816)
3. Siegfried NL, Van Deventer PJ, Mahomed FA, Rutherford GW. Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults. Cochrane Database Syst Rev. 2006;2:CD004535
4. Nuesch R, Srasuebkul P, Ananworanich J, et al. Monitoring the toxicity of antiretroviral therapy in resource limited settings: a prospective clinical trial cohort in Thailand. J Antimicrob Chemother. 2006;58(3):637-644 (Pubitemid 44288131)
5. Matheron S, Massip P, Trepo C, et al. Metabolic and clinical evaluation of lipodystrophy syndrome (LD) in HIV-1-infected adults receiving initial HAART with or without a protease inhibitor (PI): 48 week data from the CNAF3007 study. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections; 2001. Abstract 670
6. Joly V, Flandre P, Meiffredy V, et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS. 2002;16(18):2447-2454 (Pubitemid 35471693)
7. Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation. 1999;100(7):700-705 (Pubitemid 29383638)
8. Herman JS, Ives NJ, Nelson M, Gazzard BG, Easterbrook PJ. Incidence and risk factors for the development of indinavir-associated renal complications. J Antimicrob Chemother. 2001;48:355-360 (Pubitemid 32898805)
9. Dieleman JP, van Rossum AMC, Stricker BCH, et al. Persistent leukocyturia and loss of renal function in a prospectively monitored cohort of HIV-infected patients treated with indinavir. J Acquir Immune Defi c Syndr. 2003;32:135-142 (Pubitemid 36222714)
10. Easterbrook P, Phillips AN, Hill T, et al. Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK. HIV Med. 2008;9(1):47-56
11. Semba RD, Shah N, Vlahov D. Risk factors and cumulative incidence of anaemia among HIV-infected injection drug users. Int J STD AIDS. 2002;13(2):119-123 (Pubitemid 34139780)
12. White AJ. Mitochondrial toxicity and HIV therapy. Sex Transm Infect. 2001;77(3):158-173 (Pubitemid 32595736)
13. Smith CJ, Sabin CA, Lampe FC, et al. The relationship between CD4 cell nadirs and the toxicity profi les of antiretroviral regimens. Antiviral Ther. 2005;10:459-467 (Pubitemid 41151024)
14. Rossero R, Asmuth DM, Grady JJ, et al. Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature. Int J STD AIDS. 2003;14(5):350-355 (Pubitemid 36606114)
15. Moore RD, Keruly JC, Chaisson RE. Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs. AIDS. 2001;15(5):617-620 (Pubitemid 32281357)
16. Dragovic G, Milic N, Jevtovic DJ. Incidence of acute pancreatitis and nucleoside reverse transcriptase inhibitors usage. Int J STD AIDS. 2005;16:427-429 (Pubitemid 40868379)
17. Dragovic G, Jevtovic DJ. Nucleoside reverse transcriptase inhibitor usage and the incidence of peripheral neuropathy in HIV/AIDS patients. Antiviral Chemother. 2003;14:281-284 (Pubitemid 37509384)
18. Gazzard B, for the BHIVA writing committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med. 2008;9:795-848
19. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA. 2006;296(7):827-843 (Pubitemid 44223106)
20. Clumeck N, Pozniak A, Raffi F, EACS Executive Committee. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med. 2008;9(2):65-71 (Pubitemid 351228129)
21. Bollerup AR, Donoghoe MC, Lazarus JV, Nielsen S, Matic S. Access to highly active antiretroviral therapy (HAART) in the WHO European Region 2003-2005. Scand J Public Health. 2008;36:183-189 (Pubitemid 351359373)
22. Sabin CA, Lampe F, Chaloner C, et al. An audit of antiretroviral treatment use in HIV-infected patients in a London clinic. HIV Med. 2003;4(2):87-93
23. Subbaraman R, Chaguturu SK, Mayer KH, Flanigan TP, Kumarasamy N. Adverse effects of highly active antiretroviral therapy in developing countries. Clin Infect Dis. 2007;45(8):1093-1101 (Pubitemid 47580363)
24. Oyugi JH, Byakika-Tusiime J, Ragland K, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fi xed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS. 2007;21(8):965-971 (Pubitemid 46684328)
25. Canestri A, Sow PS, Vray M, et al. Poor effi cacy and tolerability of stavudine, didanosine, and efavirenz-based regimen in treatment-naive patients in Senegal. MedGenMed. 2007;9(4):7
26. Rey D, Krebs M, Partisani M, et al. Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients. J Acquir Immune Defi c Syndr. 2006;43(5):530-534 (Pubitemid 44885618)
27. Zhou J, Kumarasamy N, Ditangco R, et al. The TREAT Asia HIV Observational Database: baseline and retrospective data. J Acquir Immune Defi c Syndr. 2005;38(2): 174-179 (Pubitemid 40189324)
28. Hofer CB, Schechter M, Harrison LH. Effectiveness of antiretroviral therapy among patients who attend public HIV clinics in Rio de Janeiro, Brazil. J Acquir Immune Defi c Syndr. 2004;36(4):967-971 (Pubitemid 38944093)
29. Lichtenstein KA, Delaney KM, Armon C, et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1 infected patients. J Acquir Immune Defi c Syndr Hum Retrovirol. 2003;32:48-56 (Pubitemid 36091484)
30. Rakotoambinina B, Medioni J, Rabian C, Jubault V, Jais J-P, Viard JP. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor. J Acquir Immune Defic Syndr Hum Retrovirol. 2001;27:443-449 (Pubitemid 32801072)
31. van der Valk M, Gisolf EH, Wit FW, Japour A, Weverling GJ, Danner SA. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS. 2001;15(7):847-855 (Pubitemid 32424388)
32. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-F58 (Pubitemid 28190689)
33. Sabin CA, Smith CJ, Gumley H, et al. Late presenters in the era of HAART: uptake of and responses to antiretroviral therapy. AIDS. 2004;18(15):2145-2151 (Pubitemid 39463679)
34. UNAIDS. 2006. http://data.unaids.org/pub/Report/2006/2006-country- progress-report-serbia-en.pdf.